Novartis Tries Again in Parkinson’s, Putting Up $200M for Arrowhead’s RNAi Therapy
Novartis, which already has experience with RNA interference therapies, is now turning to this modality as a potential way to treat Parkinson’s disease. The pharmaceutical giant is licensing rights to an Arrowhead Pharmaceuticals RNAi therapy designed to inhibit production of alpha synuclein, a protein associated with Parkinson’s progression.
Pharma Is Reclaiming Control Over Patient Experience. What Does It Mean For The Hub Model?
AI can now flag where patients are getting stuck — from enrollment delays to dropped calls — while also enabling new, compliant ways to analyze these interactions at scale. But surfacing the issue is just the first step.
My Mold Illness Nearly Broke Me — Let’s Ensure Others Get the Care They Deserve
Symptoms often get labeled as anxiety, chronic fatigue, early neurodegeneration, IBS, or fibromyalgia. How to prevent the root cause — mold exposure — from going unrecognized.
Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug
Injectable Leqembi permits weekly maintenance dosing of the Eisai and Biogen Alzheimer’s disease drug that may be done at a patient’s home. Other recent notable regulatory news includes several rare disease drug approvals and narrower FDA nods for Covid-19 vaccines.
4 Notable Health Tech Funding Announcements in August
Health tech companies made several major funding announcements in August. Here is a list of some of the biggest funding rounds.